希瑪眼科(03309.HK)2019年度經調整淨利潤下降12.3%至3912.2萬港元
格隆匯3月31日丨希瑪眼科(03309.HK)發佈全年業績,截至2019年12月31日止年度,公司實現收入5.76億港元,同比增長34.2%;年內經調整淨利潤3912.2萬港元,同比下降12.3%;基本每股盈利3.96港仙;擬派末期股息每股2港仙。
2019年度的總收益較2018年度的總收益增長34.2%,除視力輔助產品銷售增加61.7%外,增長主要來自於提供眼科服務產生的收益增長至5.285億港元,增幅為32.2%,是由於公司進行的手術數目及於香港及內地的眼科醫生及醫生人數增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.